Healthcare: Why This $6 Billion Biotech Stock Is Skyrocketing 70% in November

<p>A flurry of news has investors clamoring to add Nektar Therapeutics to their portfolios. Plus, we explain why investors are disappointed by Loxo Oncology’s good news and how a new smart pill could change medicine forever.</p>